Evidence map›Paper›PMID 40755153›Full record

ArticleNMR in biomedicine2025

Evaluating the Combined Effect of a Choline Kinase Inhibitor and Temozolomide Therapy in a Mouse Model of Glioblastoma Using

Tareq Alrashidi, Sourav Bhaduri, Elisabeth Non Gash, Mohesh Moothanchery, Christopher Ball, Mahon L Maguire, Lorenzo Ressel, Harish Poptani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NMR in biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tareq AlrashidiCentre for PreClinical Imaging, University of Liverpool, Liverpool, UK.
Sourav BhaduriInstitute for Advancing Intelligence (IAI), TCG CREST, Kolkata, India.
Elisabeth Non GashCentre for PreClinical Imaging, University of Liverpool, Liverpool, UK.
Mohesh MoothancheryCentre for PreClinical Imaging, University of Liverpool, Liverpool, UK.
Christopher BallCentre for PreClinical Imaging, University of Liverpool, Liverpool, UK.
Mahon L MaguireCentre for PreClinical Imaging, University of Liverpool, Liverpool, UK.
Lorenzo ResselDepartment of Veterinary Anatomy Physiology and Pathology, University of Liverpool, Chester, UK.
Harish PoptaniCentre for PreClinical Imaging, University of Liverpool, Liverpool, UK.

Funding

Isle of Man Anti-Cancer Research CharityMinistry of Education, Kingdom of Saudi Arabia
6 · The paper itself

Abstract

This study evaluated the therapeutic efficacy of combining a choline kinase alpha (ChoKα) inhibitor, MN58b, and temozolomide (TMZ) in a syngeneic GL261 glioblastoma (GBM) mouse model. It used MR spectroscopy (MRS) and intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI) to assess metabolic and microstructural changes within the tumor. Fifty-two C57BL/6 mice had GL261 cells implanted intracranially and were divided into four groups: saline control, MN58b, TMZ, and MN58b + TMZ (n = 16, 14, 11, and 11, respectively). Treatments were administered for 5 days, starting 10 days post-implantation. MRI scans (T

Indexed as

Brain NeoplasmsCholine KinaseDacarbazineDiffusion Magnetic Resonance ImagingGlioblastomaProton Magnetic Resonance SpectroscopyAnimalsCell Line, TumorDisease Models, AnimalMiceMice, Inbred C57BLTemozolomideCholine KinaseDacarbazineTemozolomidecancerGBMglioblastomaIVIMmicrostructureMR spectroscopytreatment response

Identifiers

PMID40755153
PMCPMC12319478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.